



LYSA-LYSARC and IFLI launch BIDIFLY, a €7.5M collaborative research program using artificial intelligence to better understand Follicular Lymphoma and develop new therapeutic tools.

The LYSA-LYSARC cooperative group, an international leader in basic, translational and clinical research on lymphomas, and the Institute for Follicular Lymphoma Innovation (IFLI), a private global non-profit foundation, based in California, are thrilled to announce their research partnership focused on using advanced artificial intelligence tools to elucidate the biology of follicular lymphoma (FL) and accelerate the development of innovative FL treatments. FL is the second most common form of non-Hodgkin lymphoma with significant unmet medical need due to the lack of understanding of the drivers and signatures of disease progression.

LYSA-LYSARC and IFLI designed their four-year research program, called BIDIFLY (Biological and Imaging Data Integration for Follicular Lymphoma Research), to unravel the complexity of FL heterogeneity, identify new prognostic and diagnostic biomarkers, advance monitoring tools, and ultimately develop novel treatments. BIDIFLY will involve world-class scientists and clinicians in lymphoma research, utilizing cutting-edge tools and technologies to gather comprehensive multi-omics data. The data will be analyzed using IA technologies to more specifically characterize this heterogeneous disease, identify early biomarkers of high-risk patients, and lay the groundwork for optimizing therapeutic targets.

“This first IFLI / LYSA-LYSARC collaboration should enable game-changing advances in research on follicular lymphoma in the best interest of patients suffering from this type of cancer”

— Pr F. Morschhauser, President of LYSA/LYSARC

“We are thrilled to launch this partnership with internationally renowned scientific leaders in lymphoma clinical research. This collaboration with LYSA-LYSARC marks a significant milestone for IFLI in advancing our commitment to accelerate the development of treatments and ultimately a cure for FL.”

— Andy Peykoff, Chairman of the Board of IFLI

LYSA-LYSARC and IFLI will formally present the BIDIFLY program to the press in March 2024, during a meeting set to take place in Paris.

About the LYSA-LYSARC

LYSA, The Lymphoma Study Association, is a non-profit, internationally leading, academic cooperative group gathering multidisciplinary expertise in lymphoma. Its operational structure, LYSARC, The Lymphoma Academic Research Organization, has all the integrated functions and platforms dedicated to pathology, biology and imaging to conduct clinical studies and real-world registries, as well as exploratory research programs. The LYSA has more than 500 members, researchers and medical experts, with a network of about 90 clinical research centers in France, Belgium and Portugal. The LYSA's missions are to promote clinical research, to improve prevention, care, and treatment of patients and to disseminate knowledge about all types of lymphoma.

About IFLI

The Institute for Follicular Lymphoma Innovation is a global, multi-arm, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for people with follicular lymphoma. IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel technologies, therapeutics and/or biomarkers for the treatment of follicular lymphoma and to understand the biology of follicular lymphoma in patients at high risk of progression and transformation. The foundation deploys its annual budget across grants, project-based partnerships, and venture philanthropy investments to achieve its innovation goals.

Media contact: LYSA – LYSARC
Aurélie ONNIS | Head of Communication
+33 (0) 6 85 33 94 72
aurelie.onnis@lysarc.org

Press Release
December, 2023